艾司奥美拉唑联合莫沙必利治疗反流性食管炎效果及对血清CGRP、IL-4、IL-17水平的影响

Efficacy of esomeprazole combined with mosapride in treatment of patients with reflux esophagitis and the effect on serum CGRP,IL-4 and IL-17 levels

目的探究艾司奥美拉唑联合莫沙必利治疗反流性食管炎(RE)效果及对血清降钙素基因相关肽(CGRP)、IL-4及IL-17的影响。方法选取2020年1月至2021年2月浙江新安国际医院门诊治疗的RE患者110例,采用随机数字表法分为联合组55例和单一组55例。联合组使用艾司奥美拉唑+莫沙必利治疗,单一组使用艾司奥美拉唑治疗。比较两组患者治疗前、治疗结束时治疗有效率,胃动素(MTL)、胃泌素(GAS)、CGRP、IL-17、IL-23、IL-4水平,不良反应发生情况及治疗结束时、结束后4周时的复发情况。结果联合组治疗有效率明显高于单一组,差异有统计学意义(P<0.05)。两组患者治疗前胃泌素、胃动素、CGRP水平比较差异均无统计学意义(均P>0.05);治疗结束时,与单一组相比,联合组患者胃泌素、胃动素水平均为高,CGRP水平为低(均P<0.05);治疗结束时两组患者胃泌素、胃动素、CGRP水平与治疗前比较差异均有统计学意义(均P<0.01)。两组患者治疗前IL-17、IL-23、IL-4水平比较差异均无统计学意义(均P>0.05);治疗结束时,与单一组相比,联合组患者IL-17、IL-23、IL-4水平均为低(均P<0.05);治疗结束时两组患者IL-17、IL-23、IL-4水平与治疗前比较差异均有统计学意义(均P<0.01)。两组患者不良反应发生率比较差异无统计学意义(P>0.05)。联合组RE复发率明显低于单一组(P<0.05)。结论艾司奥美拉唑联合莫沙必利治疗RE,利于降低炎症因子,改善相关血清指标,疗效显著,治疗后复发率低,且安全性尚可。

Objective To investigate the clinical efficacy of esomeprazole combined with mosapride in the treatment of patients with reflux esophagitis(RE)and effects on serum interleukin-4(IL-4),interleukin-17(IL-17)and calcitonin gene-related peptide(CGRP)levels.Methods A total of 110 RE patients treated in the outpatient department of Zhejiang Xin'an International Hospital from January 2020 to February 2021 were enrolled and randomly divided into two groups with 55 cases in each group.The control group was treated with esomeprazole,and the study group was treated with esomeprazole combined with mosapride.The efficacy of the two groups were compared;the motilin(MTL),gastrin(GAS)and IL-4,IL-17,IL-23,CGRP levels were measured before and after treatment;the adverse reactions and recurrence were observed.Results The treatment efficiency of the combined group was significantly higher than that of the single group(P<0.05).At the end of the treatment,compared with the single group,the serum gastrin and motilin levels were significantly higher,and the serum levels of IL-17,IL-23,IL-4,and CGRP in the combined group were significantly lower in the combined group(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05),while the recurrence rate of the combined group was lower than that of the single group(P<0.05).Conclusion Esomeprazole combined with mosapride in the treatment of reflux esophagitis is effective and safe with low recurrence rate,which also facilitates the reduction of inflammatory factors and improvement of relevant serum indexes.